Disposable Components in Aseptic Processing - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Disposable Components in Aseptic Processing
The authors discuss current and future disposable technologies and outline the validation and qualification steps that would be required for a possible disposable process stream.


Pharmaceutical Technology


Future disposability


Figure 3: Possible disposable process stream.
During the past 10 years, disposable technology innovations surfaced rapidly, and the nondisposable gaps within a biopharmaceutical process are now closing. There are still process steps or specific equipment parts that either will evolve into disposable systems or will be kept and integrated into a hybrid state. How total processes will look like in the future are only predictions, but developments of new disposable process components show the trend toward a total disposable process, at least in the small-scale volume streams (see Figure 3.)

Such a process would require careful planning because the volumes within a process can change drastically, process steps require proper timing, and essential connectivity requires being qualified. In some instances, radiofrequency identification (RFID) can be used to either to track equipment or process units or to connect the required process units together. These tags will can also create appropriate and necessary shelf-life information, because gamma-irradiated polymers have limited shelf lives.

The major items still not available as disposable units are valves and filling lines, which are able to handle fluid volumes at high speeds. There have been attempts to design filling systems, but these have not penetrated the industry as much as the above described disposable technologies. It is only a matter of time when such disposable filling equipment will be made available.

Innovative developments in disposable equipment enhance the safety in aseptic processing. Furthermore, these developments might create the possibility of a disposable factory. The benefits of complete disposability are relevant to all scales of bioprocesses, especially within the start-up phase. In early development, disposability reduces the need for major capital investments. As these technologies continue to develop critical factors such as drug cost, production cycle times, new product development time, and facility flexibility, all aseptic processing will be affected.

Validation and qualification necessities

Because most disposable devices are gamma irradiated, between 25 and 50 kGy short- and long-term, stability studies with the irradiated devices must be performed. Irradiation typically reduces the shelf life of such devices, and it must be determined what the limits are. Furthermore, the irradiation step could accelerate the degradation of the polymeric substances used, which can result in increased leachable and extractable levels. To determine the effects of irradiation and the stability of the polymer used, manufacturers subject these devices to a considerable regime of qualification tests before the device is commercialized. The qualification tests serve as a guidance by the end-user and commonly encompass, but are not limited to, the following tests:

  • Biocompatibility testing (USP ‹87› biological reactivity tests, in vitro; USP ‹88› biological reactivity tests, in vivo)
  • Mechanical properties (tensile strength, elongation at break, seal strength, air leak test)
  • Gas transmission properties (ASTM D3985: oxygen, ASTM F1249: water vapor)
  • USP ‹661› test for plastics
  • E.P. 3.1.7.: EVA for containers and tubing
  • E.P. 5.2.8. on TSE-BSE
  • TOC analysis
  • pH and conductivity
  • Extractable and leachable tests with standard solutions
  • Chemical compatibility testing
  • Protein adsorption studies
  • Endotoxin testing
  • Gamma irradiation sterilization validation
  • Bacterial ingress test.

These tests are conducted under standard settings with standard solutions. The data of these tests are available from the manufacturer.

Because qualification tests run under standard conditions, possible process specific validation requirements must be met. Such validation studies can be supported by the services of the vendor. Process validation studies would, for example, use a model solvent, but the process parameters would be within the end-user's specifications. Leachable testing with a product is commonly not possible because the product would cover any potential peaks. For this reason, model solvents are used that are similar to the solvent used within the product stream. However, tests must be conducted to determine the possible influences by the environmental conditions used in the end-user's processes. These tests will ensure the disposable device performs to the end user's specifications.

The process validation steps vary because the disposable devices have different purposes. Sterilizing-grade filters must undergo a product bacteria challenge test under an end-user's process conditions. If the actual fluid is bactericidal or bacteriostatic, then a placebo solution can be used. In any case, the influence of the process conditions and fluid toward the challenge organisms or separation mechanisms must be determined. Product hold bags or mixing bags do not need to undergo bacteria challenge tests, but they may have to undergo bacteria ingress tests. Both the filter and the bags systems must be tested for leachables or extractables. As mentioned, the end-user should take advantage of the vendor's services, which support the qualification documentation and process validation.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
43%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here